A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
3 More Generic Firms Start Voluntary Recalls of Atomoxetine Products
Nipro, Nihon Generic, and Daiichi Sankyo Espha on September 19 launched voluntary recalls for their respective generic versions of the ADHD drug atomoxetine due to the detection of potentially carcinogenic nitrosamine impurities above the government-set limit. The Ministry of Health,…
To read the full story
Related Article
- Strattera and All Generic Versions Now under Supply Restrictions in Japan
December 17, 2024
- All Versions of Lilly’s Strattera under Restricted Supplies in Japan
November 26, 2024
- Shipment Curbs Growing for Strattera Generics amid Nitrosamine Issues
November 18, 2024
- Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
- Sawai Joins List of Atomoxetine Recalls after Establishing Test Model
September 27, 2024
- Don’t Stop Taking Atomoxetine at Own Discretion: MHLW to Patients
September 4, 2024
BUSINESS
- Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief
January 20, 2025
- Cell and Gene Therapy Market Expected to Top US$20 Billion by 2028: IQVIA
January 20, 2025
- Shionogi Reels in US$375 Million HHS Funding for Preventive COVID-19 Med
January 20, 2025
- Senju Files Mochida-Partnered Dry Eye Drug in Japan
January 20, 2025
- Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket
January 17, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…